Protocol Ledger

Therapeutic Cohort ONC · ClinicalTrials.gov API v2

Oncology and Hematology: Phase II & III Clinical Trial Benchmarks

Protocol Ledger tracks 22,601 interventional Phase II and Phase III Oncology and Hematology protocols registered from 2018 through 2026, including 12,884 active studies, 3,040 completed studies, and 2,734 early-stopped studies (12.10% overall; 47.35% of closed trials).

Median Enrollment: 43.0 participants Median Completed Span: 1,269 days California Share: 3,297 studies (14.6%)

1. Reconciled Oncology and Hematology Execution & Stop-Cause Profile

Oncology and Hematology Cohort Metrics (Publication 47c4426df7e9d67d5bfe)
Clinical Trial Metric Verified Value Operational Context
Total Phase II & III Protocols (2018 to 2026) 22,601 Deterministic primary MeSH and condition-keyword assignment
Active Concurrent Pipeline 12,884 Recruiting, enrolling by invitation, and active follow-up protocols
Completed vs Prematurely Stopped 3,040 / 2,734 47.35% closed-trial attrition ratio across 5,774 closed protocols
Slow Accrual vs Safety & Futility Stops 746 / 280 / 126 Slow accrual (WS1) vs clinical safety (WS4) vs interim futility (WS5)
Physical Hospital Site Disclosure Rate 89.7% Named hospital campus participations vs anonymized CRO site slots

2. Leading Consolidated Trial Sponsors Focused on Oncology and Hematology

Consolidated Biopharma, Academic & Federal Sponsors (Oncology and Hematology Primary Focus)
Sponsor Hub Sector Protocols Active Completed FDA NDA/BLA
Sun Yat-sen University Academic / Institutional Sponsor 665 365 60 0
Fudan University Academic / Institutional Sponsor 571 352 31 0
AstraZeneca Biopharma Industry 534 300 175 81
MD Anderson Cancer Center Academic / Cooperative Group 519 344 38 0
Novartis Biopharma Industry 492 179 194 224
National Cancer Institute (NCI) Federal / NIH 458 318 52 0
Merck & Co. Biopharma Industry 439 201 195 183
Pfizer Biopharma Industry 377 143 161 418
Roche / Genentech Biopharma Industry 353 158 131 95
Memorial Sloan Kettering Cancer Center Academic / Cooperative Group 308 236 44 0
Johnson & Johnson / Janssen Biopharma Industry 300 122 123 131
Tianjin Medical University Cancer Institute and Hospital Academic / Institutional Sponsor 273 158 11 0

3. Representative Multi-Center Phase II & III Oncology and Hematology Studies

Indexed ClinicalTrials.gov v2 Study Dossiers in Oncology and Hematology
NCT Study Protocol Brief Title Sponsor Phase Status
NCT05646316 Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer NRG Oncology Phase III RECRUITING
NCT05886036 Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial National Cancer Institute (NCI) Phase II RECRUITING
NCT06661915 A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) National Cancer Institute (NCI) Phase II RECRUITING
NCT05657873 A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) Memorial Sloan Kettering Cancer Center Phase II RECRUITING
NCT07111507 A Study of Tarlatamab for People With Prostate Cancer Memorial Sloan Kettering Cancer Center Phase II RECRUITING
NCT05848765 Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy University of Birmingham Phase II RECRUITING
NCT05751434 A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer City of Hope Phase II RECRUITING
NCT05188508 Pembrolizumab, Olaparib, and Temozolomide for People With Glioma Memorial Sloan Kettering Cancer Center Phase II RECRUITING
NCT06451861 Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML Guangdong Provincial People's Hospital Phase II RECRUITING
NCT06882057 Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol Institute of Hematology & Blood Diseases Hospital, China Phase II/III RECRUITING
NCT06855810 Newly-diagnosed Pediatric T-cell ALL Protocol Institute of Hematology & Blood Diseases Hospital, China Phase II/III RECRUITING
NCT06764238 Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol Institute of Hematology & Blood Diseases Hospital, China Phase II/III RECRUITING
NCT05806931 Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer Rutgers, The State University of New Jersey Phase II RECRUITING
NCT05559164 Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted Rutgers, The State University of New Jersey Phase II RECRUITING
NCT07450599 A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer. Bayer Phase II RECRUITING
NCT05011383 High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers VA Office of Research and Development Phase II RECRUITING

Related Therapeutic Condition Hubs & Crosswalks

Compare adjacent clinical cohorts: Rare Genetic, Women's Health, and Other · Infectious Disease and Vaccines · Neurology, Psychiatry, and Pain · Immunology, Rheumatology, and Dermatology, browse the interactive Hospital & Sponsor Directory, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI